NCT01217931 2026-01-30
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
27 trialsNCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT01034631 2022-07-11
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT00392821 2022-06-06
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01218555 2022-01-27
Study of Everolimus (RAD001) in Combination With Lenalidomide
Emory University
Phase 1 Completed
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00827359 2021-02-24
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02077933 2020-12-08
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis
Phase 1 Completed
NCT01184326 2019-10-02
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02504892 2019-03-22
Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01108445 2018-01-16
ASPEN
Duke University
Phase 2 Completed
NCT02479490 2018-01-16
PREV
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated
NCT00331409 2017-10-26
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01514448 2017-07-19
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Novartis
Phase 4 Completed
NCT00651482 2017-04-11
Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
Stanford University
Phase 2 Terminated
NCT00903175 2016-11-08
RECORD-3
Novartis
Phase 2 Completed
NCT00831480 2016-03-21
Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
Baylor College of Medicine
Phase 2 Terminated
NCT00446368 2016-03-17
RAD001
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00448149 2016-03-17
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT00303732 2016-03-03
PTK/RAD
Duke University
Phase 1 Completed
NCT01888042 2016-02-10
POORTOR
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT02056587 2014-02-06
Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
Kidney Cancer Research Bureau
Phase 4 Completed
NCT00323739 2013-07-26
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00410124 2013-01-15
RECORD-1
Novartis
Phase 3 Completed
NCT00422344 2010-02-26
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed